Iowa Mutation Modeling Program

Iowa Mutation Modeling Program

Mutation: Aβ Asp23Asn Objective: Determine whether mutation-specific changes in aggregation kinetics are sufficient to explain altered amyloid deposition patterns and clinical onset timing.

---

1. Biological Background

1.1 Genetic and Molecular Context

• Description of the Asp23Asn substitution
• Location within Aβ sequence
• Known biochemical effects (e.g., altered charge, isomerization propensity)

1.2 Reported Phenotypic Features

• Age of onset distribution
• Neuropathological characteristics
• Reported fibril properties
• Relevant clinical observations

---

2. Working Mechanistic Hypothesis

2.1 Core claim

The Iowa mutation (Aβ D23N) increases the in vivo burden of neurotoxic soluble oligomers by driving the formation of unusually stable, rapidly forming fibrils that deposit predominantly in vascular-associated, diffuse fibril “clouds” (CAA / perivascular deposits), thereby increasing catalytic fibril surface area available for oligomer generation.

2.2 Empirical anchors from Tomidokoro et al. (2010)

The working hypothesis is grounded in the following observations/arguments:

• A substantial fraction of deposited Aβ in Iowa brain tissue is post-translationally modified at residue 23: approximately 10–30% contains isoAsp23.
• D23N may act as a “fast track” to isoAsp formation because Asn deamidation typically produces isoAsp much faster than Asp isomerization (order-of-magnitude statement in the discussion).
• isoAsp-bearing molecules exhibit enhanced in vitro fibrillization kinetics relative to wild-type, and D23N strongly accelerates fibrillization (shortened lag phase; much faster ThT kinetics).
• isoAsp at other Aβ sites (e.g., positions 1 and 7) is associated with decreased proteolytic sensitivity, suggesting isoAsp23 may also contribute to impaired clearance once aggregated.

2.3 Structural/mechanistic support from Warmack et al. (2019)

Warmack et al. provide atomic-resolution structural evidence that isoAsp23 alters protofilament interfaces in a way that can plausibly increase both aggregation rate and fibril stability, and explicitly discuss that the Iowa mutation may operate similarly and/or via faster production of isoAsp23. They also report that PCMT1 does not effectively repair isoAsp23 once in aggregated forms.

2.4 Quantitative hypothesis: “surface-area amplification”

We translate the above into a quantitative causal chain:

(1) D23N increases the rate of isoAsp23 formation and/or stabilizes the fibril state. (2) Faster fibrillization and higher stability favor vascular/perivascular diffuse fibril deposition (CAA-associated “clouds”). (3) Diffuse fibrils yield higher total exposed fibril surface area per deposited mass than compact neuritic plaques. (4) Fibril surfaces catalyze oligomer generation (secondary nucleation / surface-catalyzed pathways). (5) If clearance is impaired (proteolysis resistance; limited repair; immune sink saturation), soluble oligomer concentration increases sufficiently to drive toxicity.

We treat steps (2)–(5) as a model to be constrained by data.

---

2.5 Minimal “brain-sized” production–clearance model (first-pass)

Let:

• $M(t)$ = local monomer (or soluble Aβ) concentration (mol·L⁻¹)
• $F(t)$ = fibril mass concentration (or total fibril mass in a compartment)
• $A(t)$ = total exposed fibril surface area (m²) in the relevant compartment (e.g., vascular wall + perivascular region)
• $O(t)$ = soluble oligomer concentration (mol·L⁻¹)
• $f_{\mathrm{i}\mathrm{s}\mathrm{o}}(t)$ = fraction of deposited molecules containing isoAsp23

IsoAsp formation (phenomenological): $\frac{d{f}_{\mathrm{i}\mathrm{s}\mathrm{o}}}{dt}=k_{\mathrm{i}\mathrm{s}\mathrm{o}}(1-f_{\mathrm{i}\mathrm{s}\mathrm{o}})-k_{\mathrm{r}\mathrm{e}\mathrm{p}\mathrm{a}\mathrm{i}\mathrm{r}}{f}_{\mathrm{i}\mathrm{s}\mathrm{o}}$

Aggregation / fibril growth (minimal): $\frac{dF}{dt}=k_n{M}^n+k_2{M}^{m}A-k_{\mathrm{c}\mathrm{l}\mathrm{e}\mathrm{a}\mathrm{r},F}F$

Here $k_2$ captures surface-catalyzed addition / secondary nucleation terms; $k_{\mathrm{c}\mathrm{l}\mathrm{e}\mathrm{a}\mathrm{r},F}$ is effective clearance of fibrillar material.

Surface area mapping (“morphology parameter”): $A(t)={\alpha }_{\mathrm{m}\mathrm{o}\mathrm{r}\mathrm{p}\mathrm{h}}F(t)$

where ${\alpha }_{\mathrm{m}\mathrm{o}\mathrm{r}\mathrm{p}\mathrm{h}}$ has units of (surface area)/(fibril mass) and encodes the difference between compact plaques vs diffuse CAA fibril clouds. The key claim is: ${\alpha }_{\mathrm{C}\mathrm{A}\mathrm{A}}\gg {\alpha }_{\mathrm{p}\mathrm{l}\mathrm{a}\mathrm{q}\mathrm{u}\mathrm{e}}$

Oligomer production on fibril surfaces: $\frac{dO}{dt}=k_{\mathrm{c}\mathrm{a}\mathrm{t}}{M}^{p}A-k_{\mathrm{c}\mathrm{l}\mathrm{e}\mathrm{a}\mathrm{r},O}O$

At quasi–steady state (fast oligomer dynamics relative to years-scale deposition), this gives: $O^{*}\approx \frac{k_{\mathrm{c}\mathrm{a}\mathrm{t}}}{k_{\mathrm{c}\mathrm{l}\mathrm{e}\mathrm{a}\mathrm{r},O}}{M}^{p}A$

Thus the “surface-area amplification” prediction is: Failed to parse (syntax error): {\displaystyle \frac{O^{*}_{\mathrm{CAA}}}{O^{*}_{\mathrm{plaque}}} \approx \frac{\alpha_{\mathrm{CAA}}}{\alpha_{\mathrm{plaque}}} \cdot \frac{F_{\mathrm{CAA}}}{F_{\mathrm{plaque}}} \cdot \left(\frac{M_{\mathrm{CAA}}}{M_{\mathrm{plaque}}}\right)^p \end{math} '''Toxicity / neuronal loss (minimal hazard model):''' Let <math>N(t)} denote viable neurons (or synapses) in a region. A minimal coupling is: $\frac{dN}{dt}=-k_{\mathrm{t}\mathrm{o}\mathrm{x}}{O}^{q}N$

which implies an exponential survival curve with an oligomer-dependent hazard.

---

2.6 What we would try to estimate (order-of-magnitude targets)

To turn the above into numbers, we need:

• ${\alpha }_{\mathrm{m}\mathrm{o}\mathrm{r}\mathrm{p}\mathrm{h}}$: surface area per unit fibril mass for (i) diffuse CAA-associated fibrils vs (ii) compact plaques.
• $k_{\mathrm{c}\mathrm{a}\mathrm{t}}$: oligomer generation flux per unit surface area (or inferred from in vitro secondary nucleation fits).
• $k_{\mathrm{c}\mathrm{l}\mathrm{e}\mathrm{a}\mathrm{r},O}$: effective oligomer clearance (proteolysis + transport + immune uptake).
• Compartments/volumes: vascular wall / perivascular space volume to convert oligomer counts to concentration.
• A toxicity mapping $k_{\mathrm{t}\mathrm{o}\mathrm{x}},q$ that can be anchored to synapse loss or neuronal death observables.

---

2.7 Immediate, testable predictions

Even with bold assumptions, the model yields falsifiable consequences:

• If CAA morphology implies ${\alpha }_{\mathrm{C}\mathrm{A}\mathrm{A}}\gg {\alpha }_{\mathrm{p}\mathrm{l}\mathrm{a}\mathrm{q}\mathrm{u}\mathrm{e}}$, oligomer load should scale with vascular/perivascular amyloid burden more strongly than with parenchymal plaque load.
• Regions with high vascular amyloid should exhibit disproportionately high markers of synaptic injury relative to plaque-centric AD, after controlling for total deposited mass.
• Interventions that reduce fibril surface availability (without necessarily reducing total mass) should reduce oligomer-associated toxicity signals more than expected from plaque mass reduction alone.

(These predictions should be linked later to specific observables: PET patterns, CSF markers, region-specific atrophy, vascular dysfunction readouts.)

---

3. Mathematical Formalization

3.1 Aggregation Kinetics Model

• Governing equations (e.g., nucleation–elongation framework)
• Definition of state variables
• Rate constants
• Conservation constraints

3.2 Mutation-Specific Modifications

• Which parameters differ from wild-type?
• Justification for parameter changes
• Sensitivity to parameter variation

3.3 Assumptions and Simplifications

• Spatial homogeneity vs heterogeneity
• Deterministic vs stochastic treatment
• Boundary conditions

---

4. Parameterization

Structured parameter table:

Parameter	Symbol	Value	Source	Experimental Context
Primary nucleation rate	k_n	...	...	in vitro aggregation assay
Elongation rate	k_+	...	...	...
Secondary nucleation rate	k_2	...	...	...

Include:

• Units
• Measurement uncertainty
• Scaling assumptions (in vitro → in vivo)

---

5. Scaling Strategy

How molecular kinetics propagate upward.

5.1 From Aggregates to Plaque Load

• Mapping monomer/polymer concentration to plaque mass
• Spatial assumptions

5.2 From Plaque Load to Imaging Signal

• Relationship to PET SUVR
• Assumed conversion functions

5.3 From Plaque Accumulation to Clinical Onset

• Threshold hypotheses
• Network vulnerability assumptions

Explicitly state which links are empirical vs theoretical.

---

6. Quantitative Predictions

Clearly enumerated, falsifiable predictions:

• Predicted shift in age of detectable amyloid PET signal
• Predicted plaque growth rate differences vs wild-type
• Predicted regional deposition differences
• Sensitivity of onset timing to kinetic parameters

Avoid vague language. Use numerical ranges where possible.

---

7. Comparison with Existing Data

• PET studies in Iowa mutation carriers
• Reported onset ages
• Neuropathological findings

Explicitly state:

• Agreement
• Discrepancies
• Unexplained features

---

8. Sensitivity and Identifiability Analysis

• Which parameters dominate model behavior?
• Are multiple parameter combinations indistinguishable?
• Which measurements would most constrain uncertainty?

This section signals modeling seriousness.

---

9. Open Problems

• Missing kinetic measurements
• In vivo vs in vitro scaling uncertainties
• Spatial heterogeneity
• Interaction with tau pathology

---

10. Next Steps

• Required data
• Computational refinement
• Proposed experimental collaborations